"AGI-1067 works by inhibiting key oxidant signals within cells of blood vessel walls that generate inflammatory processes that are key to the pathogenesis of atherosclerosis. This includes inhibition of inflammatory cytokines, chemokines and vascular adhesion molecules that participate in the initiation, growth and eventual destabilization of the plaque. Its anti-oxidant properties also play a role in its ability to inhibit the formation of oxidized LDL, a critical component in the formation of atherosclerotic plaque."@en . "investigational"@en . "AGI-1067, is a novel small molecule with anti-oxidant and anti-inflammatory properties that was discovered by AtheroGenics and designed to treat atherosclerosis of the blood vessels of the heart, or coronary artery disease."@en . . . . . . . . . . . . . . . . . . . . . . . . . "# Serebruany VL, Malinin A, Eisert C, Ong S: AGI-1067, a novel vascular protectant, anti-inflammatory drug and mild antiplatelet agent for treatment of atherosclerosis. Expert Rev Cardiovasc Ther. 2007 Jul;5(4):635-41. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17605642 # Serebruany V, Malinin A, Scott R: The in vitro effects of a novel vascular protectant, AGI-1067, on platelet aggregation and major receptor expression in subjects with multiple risk factors for vascular disease. J Cardiovasc Pharmacol Ther. 2006 Sep;11(3):191-6. \"Pubmed\":http://www.ncbi.nlm.nih.gov/pubmed/17056832"@en . . "AGI-1067"@en . . . . . . "Investigated for use/treatment in atherosclerosis, coronary artery disease, diabetes mellitus type 2, and in-stent restenosis."@en . . .